CytomX Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview

CytomX Therapeutics

07/08/2024 03:04

* CytomX Therapeutics Inc  CTMX.OQ   CTMX.O  is expected
to show a
fall in quarterly revenue when it reports  results on August 8
for the period ending January 1 0001
    * The South San Francisco California-based  company is
expected to
report a 19.1% decrease in revenue to $19.995 million from
$24.72 million a year ago, according to the mean estimate from 7
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for CytomX Therapeutics Inc
is for
a loss of 14 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for CytomX
Therapeutics Inc is $3.59​, above​ its last closing price
of $1.26. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.08       -0.08      0.01      Beat    305.2
 Jan. 1 2024   0.01        -0.03      0.01      Beat    135
 Jan. 1 0001   -0.15       -0.19      0.04      Beat    121.2​
 Jan. 1 0001   -0.18       -0.20      -0.02     Beat    90.2
 ​​Mar.        -0.12       -0.11      -0.43     Missed  52.7
 31 2023                                                
 Jan. 1 0001   -0.17       -0.24      -0.43     Missed  -82.5​
 Sep. 30 2022  -0.29       -0.36      -0.35     Beat    -14.5
 Jan. 1 0001   -0.36       -0.36      -0.37     Missed  -2.8
 This summary was machine generated August 7 at 02:03 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)